ArticleJournal of Cancer2026
LH2 Promotes Tumor Progression in Oral Squamous Cell Carcinoma via EPHA7-AKT-VEGF Signaling.
Article in Journal of Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lysyl hydroxylase 2 (LH2) specifically hydroxylates lysine residues in type I collagen telopeptides. Aberrant LH2 expression has been implicated as a driver of aggressive phenotypes in multiple cancers, including oral squamous cell carcinoma (OSCC). However, the intracellular signaling mechanisms activated by LH2 overexpression remain unclear. Methods: In this study, we performed a comprehensive expression analysis to clarify LH2-driven signaling and to identify potential therapeutic targets. Stable LH2-overexpressing (LH2 O/E) OSCC cell lines were generated using a CAG-driven full-length LH2 cDNA construct. Cell proliferation assays were performed to evaluate the effects of LH2 overexpression on cell growth. Expression profiling by RNA sequencing, followed by Ingenuity Pathway Analysis, was performed to identify LH2-regulated networks. Differentially expressed genes were validated by quantitative RT-PCR and immunoblot analyses. siRNA-mediated LH2 knockdown was performed for loss-of-function studies. Results: LH2 O/E cells displayed significantly increased proliferative capacity compared with control cells. RNA sequencing identified 3,415 differentially expressed genes (1,828 upregulated and 1,587 downregulated) associated with axonal guidance signaling. Among the genes within the axonal guidance signaling network, ephrin type-A receptor 7 (EPHA7) was markedly upregulated. Increased EPHA7 expression was associated with induction of vascular endothelial growth factors (VEGFs) and increased AKT phosphorylation. Knockdown of LH2 in LH2 O/E cells reduced EPHA7 and VEGF levels and attenuated cell proliferation, supporting a functional link between LH2 and the EPHA7-VEGF axis. Conclusion: Our findings demonstrate that LH2 overexpression drives an EPHA7-VEGF signaling cascade that promotes tumor progression in OSCC. These results provide mechanistic insight into LH2-associated oncogenesis and identify a potential therapeutic target for OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.